Business Description
PTC Therapeutics Inc
NAICS : 325412
SIC : 2834
100 Corporate Court, South Plainfield, NJ, USA, 07080
Compare
Compare
Traded in other countries / regions
BH3.Germany
•
PTCT.USA
Description
PTC Therapeutics Inc is a global biopharmaceutical company focused on the discovery, development, and commercialization of orally administered, small-molecule therapeutics. Its target area is RNA biology post-transcriptional control processes of the events occurring in a cell when a RNA messenger is copied from DNA during the transcription process. The discovered products address multiple therapeutic areas, including rare disorders, such as nonsense mutations in Duchenne muscular dystrophy and oncology.
Financial Strength
3/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| Cash-To-Debt | 0.84 | |||||
| Equity-to-Asset | -0.1 | |||||
| Debt-to-Equity | -3.29 | |||||
| Debt-to-EBITDA | -1.66 | |||||
| Piotroski F-Score | 2/9 | |||||
| Altman Z-Score | -1.1 | |||||
| Beneish M-Score | -2.51 | |||||
| WACC vs ROIC | ||||||
Growth Rank
7/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| 3-Year Revenue Growth Rate | 10.4 | |||||
| 3-Year EBITDA Growth Rate | -39.6 | |||||
| 3-Year EPS without NRI Growth Rate | -39.3 | |||||
| 3-Year FCF Growth Rate | -72.7 | |||||
| 3-Year Book Growth Rate | -85.8 | |||||
| Future 3-5Y Total Revenue Growth Rate Industry Rank | 22.44 |
Momentum Rank
4/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| 5-Day RSI | 65.21 | |||||
| 9-Day RSI | 68.28 | |||||
| 14-Day RSI | 69.59 | |||||
| 6-1 Month Momentum % | 18.89 | |||||
| 12-1 Month Momentum % | 27.38 |
Liquidity Ratio
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| Current Ratio | 1.22 | |||||
| Quick Ratio | 1.2 | |||||
| Cash Ratio | 0.89 | |||||
| Days Inventory | 160.16 | |||||
| Days Sales Outstanding | 66.49 | |||||
| Days Payable | 218.26 |
Dividend & Buy Back
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| 3-Year Average Share Buyback Ratio | -11.9 |
Profitability Rank
3/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| Gross Margin % | 94.24 | |||||
| Operating Margin % | -62.26 | |||||
| Net Margin % | -89.89 | |||||
| ROE % | -9218.07 | |||||
| ROA % | -28.92 | |||||
| ROIC % | -28.6 | |||||
| ROC (Joel Greenblatt) % | -314.45 | |||||
| ROCE % | -31.04 |
GF Value Rank
4/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| PS Ratio | 6.07 | |||||
| EV-to-EBIT | -8.56 | |||||
| EV-to-Forward-EBIT | -17.28 | |||||
| EV-to-EBITDA | -10.72 | |||||
| EV-to-Forward-EBITDA | -20.28 | |||||
| EV-to-Revenue | 6.28 | |||||
| EV-to-Forward-Revenue | 5.46 | |||||
| EV-to-FCF | -9.19 | |||||
| Earnings Yield (Greenblatt) % | -11.68 |
Guru Trades
See DetailsEMBED
SAVE
Insider Trades
See DetailsEMBED
SAVE
Executives
EMBED
Analyst Estimate
Key Statistics
| Name | Value | ||
|---|---|---|---|
| Revenue (TTM) (Mil €) | 555.798 | ||
| EPS (TTM) (€) | -7.035 | ||
| Beta | 0.39 | ||
| Volatility % | 48.5 | ||
| 14-Day RSI | 69.59 | ||
| 14-Day ATR (€) | 1.287384 | ||
| 20-Day SMA (€) | 45.875 | ||
| 12-1 Month Momentum % | 27.38 | ||
| 52-Week Range (€) | 24.2 - 52.5 | ||
| Shares Outstanding (Mil) | 71.54 |
Piotroski F-Score Details
Year:
| Component | Result | ||
|---|---|---|---|
| Piotroski F-Score | 2 | ||
| Positive ROA | |||
| Positive CFROA | |||
| Higher ROA yoy | |||
| CFROA > ROA | |||
| Lower Leverage yoy | |||
| Higher Current Ratio yoy | |||
| Less Shares Outstanding yoy | |||
| Higher Gross Margin yoy | |||
| Higher Asset Turnover yoy |
PTC Therapeutics Inc Filings
| Document | Form | Filing Date | ||
|---|---|---|---|---|
| No Filing Data | ||||